Delayed Spontaneous Remission In A Child With Primary Acquired Chronic Pure Red Cell Aplasia
Khalil, A., Elhasid, R., Ben Barak, A., & Ben Arush, M. W. (2010). Delayed spontaneous remission in a child with primary acquired chronic pure red cell aplasia. Pediatric hematology and oncology, 27(7), 574–580. https://doi.org/10.3109/08880018.2010.493577
View Original Source →Abstract
The acquired form of pure red cell aplasia (PRCA) presents either as an acute self-limited disease, predominantly seen in children, or as a chronic illness more frequently seen in adults with rare spontaneous remissions. A 14-year-old boy presented with pallor, without hepatosplenomegaly, jaundice, lymphadenopathy, petechiae, or any other apparent abnormalities. Isolated anemia in the presence of normal white cell and platelet counts with a marrow of normal cellularity and absence of erythroblasts but normal myeloid cells and megakaryocytes revealed the diagnosis of PRCA. All possible investigations excluded secondary causes of PRCA. The patient required packed red cell transfusions every 2 to 3 weeks. He failed therapy with intravenous immunoglobulin, corticosteroids, cyclosporine A plus corticosteroids, antithymocyte globulin, anti-CD 20 (rituximab), and erythropoietin (EPO). He showed a severe, resistant, and transfusion-dependent PRCA. Spontaneous remission with normal hemoglobin and reticulocyte levels was dramatic 6.5 years after the diagnosis of PRCA and 3.6 years after his last treatment.
Case Details
Disease Location
Blood
Personal Characteristics
14 years old israeli arab boy
Clinical Characteristics
History of pallor. Symptoms of upper respiratory tract infection. Diagnosis of aquire pure red cell aplasia.
Remission Characteristics
Dramatic spontaneous remission 6.5 years from the diagnosis of prca
Treatment & Mechanisms
Proposed Remission Mechanisms
Some unknown factor may have been contained in the transfused packed red cells and inhibited or adsorbed autoantibodies or inhibited its production
Clinical Treatment
Blood transfusion. Treatment with intravenous immunoglobulin. Cyclosporin a. Prednisone. Antithymocyte globulin.anti-CD20 monoclonal antibody (rituximab).horse atg. High-dose methylprednisolone. Iron chelation.